Company Long-Term Liabilities: ImageneBio Inc (IMA)

Brandmark of Ikena Oncology (IMA)

The market valuation dynamics for ImageneBio Inc (IMA), which specializes in immunological drugs, correlate with partnerships for the development of targeted tumor therapies, where the indicator equals 0.00. High R&D expenditures and stringent FDA oversight create significant barriers to entry for competitors. Meanwhile, ImageneBio Inc (IMA) maintains its human capital potential in cancer signaling pathways by attracting clinical experts through a stock option system.

IMA ImageneBio Inc: Company Long-Term Liabilities in the range 07/29/2025 - 10/29/2026

Summary analytical data breakdowns for Ikena Oncology (IMA)

- stock quotes and analyst forecast:
Price Performance Chart ImageneBio|IMA - Price Target Chart
- company stock exchange capitalization indicators:
Market Valuation Ikena Oncology|IMA - Enterprise Value
- shareholders' equity book value data:
Book Value per Share Ikena Oncology|IMA - Company Net Assets|Market Value to Book Value ikenaoncology.com|IMA - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Coefficient ImageneBio Inc|IMA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio ImageneBio|IMA - Company Debts|Debt to Book Value Ikena Oncology|IMA - Company Long-Term Liabilities|Company Short-Term Debts Ikena Oncology|Immediate Liquidity Ratio ikenaoncology.com
- business earnings and investment ratios data:
IMA - Net Profit
Analysis of all company metrics:IMA - ImageneBio Inc
Signature product of Ikena Oncology, Inc.

Long-term debt separates stable enterprises from high-risk startups, measuring obligations with maturities exceeding one year to assess financial leverage. Given the cash burn of ImageneBio Inc (IMA) and the hypothetical nature of its oncology drug returns, analyzing the business's long-term debt levels determines how critical creditor pressure is amid pipeline restructuring and the risks of development program closures.

Competitor analysis for ImageneBio Inc

Company Long-Term Loans and Borrowings ARGX|BNTX - Company Long-Term Debt|abivax.com (ABVX) - Company Long-Term Liabilities|ADMA: Company Long-Term Debts|Protagonist Corp (PTGX) - Company Long-Term Debts|Company Long-Term Liabilities IMVT|KNSA: Company Long-Term Loans and Borrowings|Company Long-Term Debts GRFS|Long-Term Debt Volume Adaptive Biotech|Company Long-Term Debt Celldex CLDX|AUPH - Company Long-Term Liabilities|BCRX - Company Long-Term Debt|veratx.com (VERA) - Company Long-Term Liabilities|DNTH (Dianthus Therapeutics, Inc.) - Company Long-Term Liabilities|Pharvaris NV (PHVS) - Company Long-Term Debts|Company Long-Term Debt AbCellera Biologics|Company Long-Term Indebtedness TRML (Tourmaline)|Company Long-Term Debts PGEN|PHAR - Long-Term Debt|Company Long-Term Debts NKTR (Nektar Therapeutics Inc.)|Long-Term Debt Volume Upstream Bio, Inc. (UPB)|ZBIO - Company Long-Term Debt|Immunome Bio (IMNM) - Company Long-Term Liabilities|GOSS: Company Long-Term Debts|kalvista.com (KALV) - Company Long-Term Debts|SEPN (Septerna) - Company Long-Term Debts|PVLA - Long-Term Indebtedness|Company Long-Term Debts SVRA|RIGL - Long-Term Debt|Company Long-Term Debt AnaptysBio, Inc. ANAB|ATXS: Company Long-Term Indebtedness|enGene - Company Long-Term Debts|Long-Term Debt rapt.com|JBIO: Company Long-Term Debts|ACRS (Aclaris Therapeutics, Inc) - Company Long-Term Debt|KYTX (Kyverna Therapeutics) - Company Long-Term Debts|tizianalifesciences.com (TLSA) - Long-Term Debt Volume|Company Long-Term Debt Cabaletta Bio (CABA)|VTYX - Long-Term Debt|Theratechnologies Inc - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings AVTX|Eledon Pharmaceuticals - Company Long-Term Debts|Long-Term Debt Volume agenusbio.com AGEN|Climb Bio (CLYM) - Company Long-Term Debt|Company Long-Term Indebtedness ZURA|ATYR (aTyr) - Company Long-Term Debts|Company Long-Term Liabilities Adagene Corp (ADAG)|Company Long-Term Debts STTK|Long-Term Debt Volume equilliumbio.com|Company Long-Term Debt Connect Biopharma Holdings Limited CNTB|IMUX - Company Long-Term Liabilities|Atara Biotherapeutics Inc - Company Long-Term Debts|IFRX - Company Long-Term Debts|X4 Pharmaceuticals (XFOR) - Company Long-Term Debt|Long-Term Liabilities ACET (Adicet Bio, Inc.)|CELU (Celularity Inc) - Company Long-Term Debts|INMB: Company Long-Term Loans and Borrowings|Company Long-Term Debts BRNS|Company Long-Term Debts Kezar Life Sciences Inc (KZR)|Company Long-Term Debt SAB Biotherapeutics SABS|Company Long-Term Loans and Borrowings AKTX|ENLV - Company Long-Term Debt|Q32 Bio Inc. (QTTB) - Company Long-Term Liabilities|GOVX: Company Long-Term Debts|Edesa Biotech Corp (EDSA) - Company Long-Term Debts|Company Long-Term Liabilities IBIO|CARM: Company Long-Term Loans and Borrowings|Company Long-Term Debts XTLB|Long-Term Debt Volume boltbio.com|Company Long-Term Debt HCW Biologics HCWB|APVO - Company Long-Term Liabilities|AIM - Company Long-Term Debt|Aditxt (ADTX) - Company Long-Term Liabilities|GRI (GRI Bio) - Company Long-Term Liabilities|XORTX Therapeutics Inc (XRTX) - Company Long-Term Debts|Company Long-Term Debt ReShape Lifesciences|Company Long-Term Indebtedness REVB (Revelation Biosciences Corp)|Company Long-Term Debts INDP|SCNI - Long-Term Debt|Company Long-Term Debts CALI (CalciMedica)|Long-Term Debt Volume Affimed NV (AFMD)|ALLK - Company Long-Term Debt|HOOKIPA Pharma Inc. (HOOK) - Company Long-Term Liabilities|IGMS: Company Long-Term Debts|iteostherapeutics.com (ITOS) - Company Long-Term Debts|OCEA (Ocean Biomedical) - Company Long-Term Debts|TCBP - Long-Term Indebtedness|Company Long-Term Debts THRD